The National Cancer Institute recognizes CytoFind™ as a powerful tool that enables real-time monitoring of circulating tumor cells (CTCs), allowing for accurate prediction of therapeutic responses. By matching patients with compatible therapies, the technology can mitigate side effects and adverse events.
FACIT, a commercialization venture group, backs Cellular Analytics in an initial seed funding round. Capital from FACIT’s Compass Rose Oncology Fund will be used to develop the non-invasive, commercial prototype of the CytoFind™ technology.
In a busy year for CTC capture and detection, several academic and commercial groups develop novel techniques. With growing interest in the technology, the US National Cancer Institute announces plans to fund research for integrating imaging and liquid biopsies. Cellular Analytics pushes forward with CytoFind™, allowing for real-time measurement of expressed surface proteins and mRNA content.